 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz= Reporter Kim Jisun] Celltrion's autoimmune disease treatment "ZYMFENTRA" has been listed on the prescription book of major prescription drug care companies (PBM) in the United States.
Celltrion announced on August 8 that ZYMFENTRA has recently completed a prescription book listing contract with one of the top three PBMs in the United States. The exact name of the PBM is not currently available.
ZYMFENTRA was developed by changing "Ramsima" (component name Infliximab), the existing Celltrion's intravenous injection-type biosimilar for autoimmune diseases, to a self-injectable subcutaneous injection type, and was approved as a new drug in the U.S. in October last year.
Since the U.S. specializes in managing prescription drugs, the listing of the PBM list means that it has been incorporated into the U.S. health insurance benefit system. The three largest PBMs in the United States account for 80% of the total insurance market.
Celltrion believes that the combination of the contract with small and medium-sized PBM, which has already signed the contract, will make it possible for about 40 percent of subscribers in the entire U.S. private insurance market.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
